Full Phase 3 melanoma data arrives at ESMO on Oct. 24. Investors have priced a conclusion without...
Premium ticket revenue beat main cabin in Q2. Delta reports Oct. 9.
Wednesday’s 1.37% bank-led rally to 186,340 gives bulls a fragile cushion before a first round that almost...
Anthropic’s IPO prospectus flags $518B of compute obligations.
CEO succession clarity and a record deal calendar make GS compelling as rising long-term rates knock the...
With 54% of Zenkuda patients at six-month dosing and a Q4 BLA plan, the stock surge may...
Warren’s probe raises a question investors have dodged: how much of the AI capex boom rests on...
August’s 4.2% profit growth, the weakest of 2026, shows what Sept. 30’s PMI may confirm and what...
August industrial profits rose 4.2%, the slowest pace of the year, with official surveys due Wednesday and...
The FDA approved Onswik on September 23. The harder question is whether Lilly can manufacture it fast...